Insights on the major trends in aging disorders and pain conditions including the development of targeted therapies in clinical trial designs and patient care.
The manifestations and effects of TBI are varied and impact diverse populations. To improve prevention and therapy, we need to conduct further clinical research to evaluate and validate better strategies for diagnosis and disease characterisation. A better understanding of how TBI — mild and severe — manifests, can lead to better identification of biomarkers, and the development of prevention and treatment strategies.Read the whitepaper
While there are many advances in Parkinson’s Disease (PD), such as identification of new biomarkers to measure disease progression, valuable insights in study design coming from Alzheimer’s Disease trials, and creative approaches for patient recruitment, challenges still remain in this therapeutic area.Read the whitepaper
There has been an increased prevalence of lifetime substance abuse, creating an urgent need for innovative pain medications without the use of opioids. Unfortunately, clinical development of non-opioid pain medications has been hindered by a massive placebo-response.In our whitepaper, we discuss the aspects of pain studies that sponsors will need to consider to ensure success of their chronic pain trial model.Read the whitepaper
Apart from the need to better manage symptoms in advanced stages of Parkinson's disease, there is an even greater need to develop neuro-protective or neuro-regenerative therapies.
Patient registries need to be offering more support and convenience to ensure greater engagement and enrolment in clinical trials.
A thought leadership article by Peter Schueler and Haichen Yang on the challenges, advancements and role of technology.
Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development.
The atempt to develop a causal treatment against the progression of Alzheimer’s disease is an unparalleled series of nearly two decades of failures in drug development.
Research suggests that CNS drugs are 45% less likely to progress from Phase III to regulatory filing than other non CNS drugs.
What are the proven benefits, which populations to target and what are the current challenges?
ICON’s experience of CNS, Pain and Ageing related disorder studies comprises global and regional clinical research in all major areas of neurology, psychiatry and pain research, and all phases of clinical drug development. Read more about ICON's services.Read more about ICON's services in CNS, Pain and Ageing related disorders